Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ewha Universty - Industry Collaboration Foundation currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. The portfolio's current activity is extremely focused, with only a single active point of prosecution at the USPTO.
The busiest examiner for this applicant is ZARA, JANE J, who is managing 1 pending office action. Because the busiest examiner pending count is 1, there is no clustering of multiple applications under this examiner. This allows the practitioner to tailor their response specifically to the requirements and examination history of this individual within the Biotechnology & Pharmaceuticals sector, as only 1 matter is assigned to this individual.
With only 1 pending office action, the foundation is managing a low volume of active prosecution. The involvement of only 1 distinct examiner and 1 distinct art unit simplifies the strategy, as there are no competing deadlines or varying examiner perspectives to reconcile. This streamlined profile indicates that the current focus is entirely on resolving the specific issues presented in this single pending action within the Biotechnology & Pharmaceuticals technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266463 | NUCLEIC ACID MOLECULES WITH INCREASED GENE SILENCING ACTIVITY AND USES THEREOF | ZARA, JANE J | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18266463 | NUCLEIC ACID MOLECULES WITH INCREASED GENE SILENCING ACTIVITY AND USES THEREOF | ZARA, JANE J | 1637 | §112 | Final Rejection | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEwha Universty - Industry Collaboration Foundation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jane J Zara has the most, with 1 of Ewha Universty - Industry Collaboration Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
